Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail of cancer drugs shows promise in early trial

NCT ID NCT06806852

Ongoing Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 24, 2026

Summary

This study tests whether combining three different antibodies—BI 770371, pembrolizumab, and cetuximab—can shrink tumors in people with head and neck cancer that has spread or come back. About 91 adults are randomly assigned to one of three treatment groups. The goal is to see if the combinations are safe and effective compared to pembrolizumab alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • "Prof. Dr. Alexandru Trestioreanu" Oncology Institut

    Bucharest, 022328, Romania

  • ARENSIA Exploratory Medicine

    Chisinau, MD-2025, Moldova

  • ARENSIA Exploratory Medicine LLC

    Tbilisi, 0112, Georgia

  • Abdurrahman Yurtaslan Oncology Training and Research Hospital

    Ankara, 06200, Turkey (Türkiye)

  • Adana City Hospital

    Adana, 01220, Turkey (Türkiye)

  • Andrew Love Cancer Centre

    Geelong, Victoria, 3220, Australia

  • Ankara Bilkent City Hospital

    Ankara, 06800, Turkey (Türkiye)

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, 37126, Italy

  • CTR Leon Berard

    Lyon, 69373, France

  • CTR Oscar Lambret

    Lille, 59020, France

  • Cantonspital Aarau

    Aarau, 5001, Switzerland

  • Center of Oncology of the Lublin Region St. Jana z Dukli

    Lublin, 20090, Poland

  • Centro Oncologico Personalizado

    México, 06760, Mexico

  • Centro Oncológico Internacional

    Tlajomulco de Zuñiga, 45640, Mexico

  • Clinexpert Gyongyos

    Gyöngyös, 3200, Hungary

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto

    São José do Rio Preto, 15090-000, Brazil

  • Gosford Hospital

    Gosford, New South Wales, 2250, Australia

  • HOP Timone

    Marseille, 13385, France

  • Hacettepe University Oncology Hospital

    Ankara, 06230, Turkey (Türkiye)

  • Hokkaido University Hospital

    Hokkaido, Sapporo, 060-8648, Japan

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, 29010, Spain

  • Hospital de Amor

    Barretos, 14784-400, Brazil

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Instituto Nacional de Cancerologia

    México, 14080, Mexico

  • Istanbul University Medical Faculty Capa Hospital

    Istanbul, 34093, Turkey (Türkiye)

  • Istituto Scientifico Romagnolo

    Meldola (FC), 47014, Italy

  • Japanese Foundation for Cancer Research

    Tokyo, Koto-ku, 135-8550, Japan

  • Kansai Medical University Hospital

    Osaka, Hirakata, 573-1191, Japan

  • Kobe University Hospital

    Hyogo, Kobe, 650-0017, Japan

  • Liga Norte Riograndense contra o cancer

    Natal, 59062-000, Brazil

  • M Health Fairview Clinics and Surgery Center - Minneapolis

    Minneapolis, Minnesota, 55455, United States

  • MBAL Sveta Sofia

    Sofia, 1404, Bulgaria

  • National Taiwan University Hospital

    Taipei, 10048, Taiwan

  • National University Hospital-Singapore-22806

    Singapore, 119228, Singapore

  • Norton Cancer Institute, Downtown

    Louisville, Kentucky, 40202, United States

  • Samsung Medical Center

    Seoul, 135-710, South Korea

  • Semmelweis University

    Budapest, 1083, Hungary

  • Severance Hospital

    Seoul, 03722, South Korea

  • Shizuoka Cancer Center

    Shizuoka, Sunto-gun, 411-8777, Japan

  • Siriraj Hospital

    Bangkoknoi, 10700, Thailand

  • St Bartholomew's Hospital

    London, EC1A 7BE, United Kingdom

  • Städtisches Klinikum Braunschweig gGmbH

    Braunschweig, 38114, Germany

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • The Catholic University of Korea, St.Vincent's Hospital

    Suwon, 16247, South Korea

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210, United States

  • The Royal Marsden Hospital, Chelsea

    London, SW3 6JJ, United Kingdom

  • The Royal Marsden Hospital, Sutton

    Sutton, SM2 5PT, United Kingdom

  • Unidad Clinica Farmacologica Bioemagno

    Mexico City, 04660, Mexico

  • Universität Leipzig

    Leipzig, 04103, Germany

  • Universitätsklinikum Jena

    Jena, 07743, Germany

  • Universitätsklinikum Ulm

    Ulm, 89081, Germany

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BI 770371, pembrolizumab, and cetuximab (antibodies given as infusions)

What this could lead to

If successful, this could lead to a more effective first-line treatment for metastatic or recurrent head and neck cancer, potentially shrinking tumors and improving outcomes.

What could go wrong

This is an early phase 1 trial with only 91 participants, so results may not apply to everyone. The combination of drugs may cause side effects or not work better than standard therapy.

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK SQUAMOUS CELL CARCINOMA